Cargando…
Targeted therapy of ovarian cancer including immune check point inhibitor
Epithelial ovarian cancer is the eighth most common cause of cancer-related deaths in women because most patients present with advanced stage disease at the time of diagnosis. Although cytoreductive surgery and platinum-based chemotherapy remain the gold standards of treatment, the recurrence rate o...
Autores principales: | Kim, Jin Young, Cho, Chi Heum, Song, Hong Suk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583460/ https://www.ncbi.nlm.nih.gov/pubmed/28823141 http://dx.doi.org/10.3904/kjim.2017.008 |
Ejemplares similares
-
Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021) -
Immune Check Point Inhibitor–Associated Glomerulonephritis
por: Ashour, Tarek, et al.
Publicado: (2018) -
Immune Check Point Inhibitor–Associated Endothelialitis
por: Bobart, Shane A., et al.
Publicado: (2020) -
Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy
por: Vergne-Santiago, Norma, et al.
Publicado: (2021) -
Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
por: Hou, Wanting, et al.
Publicado: (2021)